The findings from a new clinical trial conducted at the University of Sydney, University of London and University of Chicago are published in Psychological Medicine and show that more than 85 percent of those who enrolled in the trial completed treatment—almost three times the usual retention rate.
After eight months of outpatient treatment, patients in both treatment groups reported improved quality of life, reduced symptoms of mood disorders and enhanced social adjustment.
Treatment of newly diagnosed adolescents and young adults tends to focus on weight recovery but a crucial element of the trial was the decision to reprioritise how the goals of treatment were presented.
“Our goal was to peel back the negative impact of anorexia and to shift the traditional pressure to gain weight to an emphasis on improving quality of life and overall functioning,” said the study’s lead author Professor Stephen Touyz, from the Centre for Eating and Dieting Disorders at the University of Sydney.
“By refocusing the core of treatment, we were able to engage highly resistant individuals with severe and enduring anorexia nervosa in treatment, circumvent the notoriously high dropout rates and help them make their lives a little better.”
Treatment goals were set collaboratively for the study, by the care team and the patient, with less emphasis on weight gain and more on quality of life, reduction of mood disorders, and enhanced social adjustment.
Patients with severe and enduring anorexia nervosa (SE-AN) are notoriously difficult to treat. Most of them develop anorexia as adolescents and do not respond to treatment. Participants in this study had suffered from severe anorexia for at least seven years, with an average duration of illness of more than 15 years.
Anorexia nervosa has the highest mortality rate of any psychiatric disorder. Most individuals with SE-AN have been through multiple unsuccessful treatment episodes. Repeated failure leaves them with low motivation and a self-image dominated by illness.
After prolonged malnourishment, many of those with SE-AN are disabled and unable to hold a job. They often suffer from neurocognitive, cardiac or liver problems, as well as osteoporosis. Insurance companies frequently refuse to pay for treatment because so few individuals improve.
The study compared two standard treatments but modified them in ways that made them more suitable for individuals with such a profound and persistent disorder. The treatments – cognitive behavioral therapy (CBT) and specialist supportive clinical management (SSCM) – were altered to focus on retention, improved quality of life and to avoid “further failure experiences”.
The researchers enrolled 63 female patients at two clinical centres, one at the University of Sydney and one at St George’s Hospital, University of London. The University of Chicago served as the data-coordinating centre.
Thirty-one patients were assigned to CBT and 32 to SSCM with 30 outpatient therapy sessions over eight months. Results from both treatments were comparable, with significant improvements ranging from ‘moderate’ to ‘large’ on many measures. CBT had a greater impact on eating disorder symptoms and readiness to change. SSCM produced larger improvements in health-related quality of life and depression. Average BMI for both groups increased from 16.2 to 16.8, about 4 percent.
“The results were far better than most people in the field would have expected,” said Daniel Le Grange, PhD, professor of psychiatry at the University of Chicago and the principal investigator for the data-coordinating centre.
“Many of these patients were profoundly ill. The prevailing wisdom is that current treatments have not been effective and patients are best served by refeeding in the hospital setting. This study showed that specific modification of these behavioural approaches could overcome the high dropout rates and lead to meaningful positive change.”
“This study clearly shows that SE-AN patients do respond to, and benefit from, two specialised treatments when done by clinicians with specialist knowledge,” the authors wrote. “This study should provide hope for those suffering from severe and enduring AN as well as stimulate interest in the development of new psychosocial treatment approaches.”
Media enquiries: Verity Leatherdale, 02 9351 4312, 0403 067 342, email@example.com